4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0001193125-25-206203
Chief Scientific Officer sold 8,500 shares at an average $24.19 ($205,649)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bredt David Chief Scientific Officer | 2025-09-15 | Sale 10b5-1 | −5,098 | $23.88 | $121,761 | 421,544 | D |
| Bredt David Chief Scientific Officer | 2025-09-15 | Sale 10b5-1 | −3,402 | $24.66 | $83,888 | 418,142 | D |
| Open-market sales · 8,500 sh · avg $24.19 · $205,649 | |||||||
Loading xslF345X05/ownership.xml…